D. Ponomarenko

Tolerance of ramucirumab in the second-line therapy of patients with disseminated gastric cancer in the routine clinical practice of Russia

D. Stroyakovskiy, S. Gamayunov, A. Zhabina, 2019 .

Analysis of prognostic factors for survival in the Russian population of patients with disseminated gastric cancer, who received ramucirumab as secondline therapy in the RAMSELGA trial

D. Stroyakovskiy, S. Gamayunov, A. Zhabina, 2020, Meditsinskiy sovet = Medical Council.

The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study

N. O. Popova, O. S. Frolova, E. Kovalenko, 2020, Journal of Modern Oncology.

First results of durvalumab after chemoradiotherapy in locally advanced non-small-cell lung cancer in Russia

K. Laktionov, V. Kozlov, F. Moiseenko, 2022, Meditsinskiy sovet = Medical Council.

Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia

L. Bolotina, V. Gorbunova, E. Ovchinnikova, 2019, Journal of Modern Oncology.

The potential of using eribulin in patients with breast cancer, associated with brain metastasis: the scientific background and the Russian clinical experience

L. Bolotina, V. Gorbunova, S. Khokhlova, 2019, Journal of Modern Oncology.